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Background: Several questionnaires have been used to measure health related quality of life (HRQoL) in patients
with psoriasis, few have been adapted for use in Spain; none of them was developed specifically for the Spanish
population. The purpose of the study was to validate and assess the sensitivity to change of a new questionnaire to
measure HRQOL in patients with psoriasis (PSO-LIFE).
Methods: Observational, prospective, multicenter study performed in centers around Spain. Patients with active or
inactive psoriasis completed the PSO-LIFE together with other Dermatology Quality of Life Index (DLQI) and
Psoriasis Disability Index (PDI). A control group of patients with urticaria or atopic dermatitis was also included.
Internal consistency and test-retest reliability of the PSO-LIFE were assessed by calculating Cronbach’s alpha and
Intraclass Correlation Coefficient (ICC). Validity was assessed by examining factorial structure, the capacity to
discriminate between groups, and correlations with other measures. Sensitivity to change was measured using
effect sizes.
Results: The final sample included for analysis consisted of 304 patients and 56 controls. Mean (SD) age of psoriasis
patients was 45.3 (14.5) years compared to 38.8 (14) years for controls (p< 0.01). Cronbach’s alpha for the PSO-LIFE
was 0.95 and test-retest reliability using the ICC was 0.98. Factor analysis showed the questionnaire to be
unidimensional. Mean (SD) PSO-LIFE scores differed between patients with psoriasis and controls (64.9 [22.5] vs 69.4
[17.3]; p< 0.05), between those with active and inactive disease (57.4 [20.4] vs 76.4 [20.6]; p< 0.01), and between
those with visible and non-visible lesions (63.0 [21.9] vs. 74.8 [23.9]; p< 0.01). The correlation between PSO-LIFE and
PASI scores was moderate (r =−0.43) while correlations with DLQI and PDI dimensions ranged from moderate to
high (between 0.4 and 0.8). Effect size on the PSO-LIFE in patients reporting ‘much improved’ health status at study
completion was 1.01 (large effect size).
Conclusions: The present results provide substantial support for the reliability, validity, and responsiveness of the
PSO-LIFE questionnaire in the population for which it was designed.
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A number of studies have shown that psoriasis has a
marked negative impact on patient’s health related qual-
ity of life (HRQoL) as well as on the quality of life of
family members and partners of patients with psoriasis
[1]. A study by the National Psoriasis Foundation found
that 75% of patients reported that the disease had a
negative impact on the daily lives [2]. A review of 17
studies of HRQoL in psoriasis showed that patients with
the disease reported physical discomfort, impaired emo-
tional functioning, a negative body and self-image, and
limitations in daily activities, social contacts and (skin-
exposing) activities, and work [3]. Other studies have
shown that the disease has a particularly negative effect
on self-perception of body image leading to low self-
esteem, stigma, and a feeling of shame in the patient be-
cause of the lesions produced by the psoriasis [2]. Other
areas affected are sexual and personal relations due to
patients’ acute sense of shame stemming from the effect
of lesions on physical appearance [4].
Several questionnaires have been used to measure
HRQOL in patients with psoriasis, including generic
instruments, generic instruments for dermatology and
disease-specific questionnaires [5][6]. The Dermatology
Life Quality Index (DLQI) [7] and the Skindex 29 [8],
generic questionnaires for dermatology, have been used for
psoriasis. As well as other disease specific questionnaires
like the Psoriasis Disability Index (PDI) [9], the Impact of
Psoriasis questionnaire (IPSO) [10], the 12-Item Psoriasis
Quality of Life Questionnaire (PQoL-12) [11], the Psoriasis
Index of Quality of Life (PSORIQOL) [12], the Psoriasis
Life Stress Inventory (PLSI) [13], and the Questionnaire on
Experience with Skin Complaints (SF-QES) [14].
Of these, only the DLQI and the PDI have been
adapted for use in Spain [15][16]. In psoriasis patients,
the DLQI has been shown to have a notable floor effect
and a lack of sensitivity to detect changes when clinically
significant changes occur [1]. Likewise, the PDI concen-
trates largely on symptoms and only to a limited degree
on the impact of the disease on patients’ QOL. None of
these questionnaires was developed specifically for the
Spanish population and it has been shown that areas of
life which are important to measure for a given popula-
tion may not be included in instruments developed in
other cultures [17].
In an attempt to overcome some of these drawbacks
to measurement of HRQOL of patients with psoriasis in
Spain, the PSO-LIFE (Psoriasis Quality of Life) instru-
ment was developed [18]. It is a 20 item instrument cov-
ering aspects ranging from symptoms to the impact on
emotional well-being, relationships, and activities and
leisure, which had not been validated to date.
The objective of the present study was to validate the




This was an observational, prospective, multicenter
study to validate a new HRQOL instrument (PSO-LIFE)
for patients with psoriasis. Patients were included in the
study between October 2008 and May 2009, and
attended a maximum of 3 study visits over the 3 month
follow-up period. A total of 39 investigators from centers
all over Spain participated in the study.
The study protocol was approved by the Clinical Re-
search Ethics Committee of the Hospital General
Universitario de Valencia. All patients included in the study
provided their signed, informed consent to participate.
Study population
Three types of patients were included in the study.
Patients in Group A were patients with a diagnosis of
active psoriasis, patients in Group B had inactive psoriasis
at the time of inclusion, and patients in Group C were a
control group consisting of patients with active atopic
dermatitis (AD) or active chronic urticaria (CU). Inactive
psoriasis was defined as occurring when plaques remained
the same size and no new plaques appeared, even when
psoriasis was widespread [19]. Patients in groups A and B
completed 3 study visits, at baseline, and at 7 days and
3 months since baseline. Patients in Group C only attended
one study visit.
Inclusion criteria for Group A patients (patients with
active psoriasis) were: over 18 years of age with a diag-
nosis of plaque psoriasis for at least 6 months and con-
firmed by a dermatologist, who was able to complete the
study questionnaires, and who provided written,
informed consent to participate. Patients were excluded
from this group if they had guttate, erythrodermic or
pustular psoriasis, psoriatic arthritis, or psoriasis limited
to the scalp, nails, palms, or soles. The same inclusion
criteria were applied for Group B, although in that case
patients were required to have inactive psoriasis. Patients
included in the control group were required to have a
confirmed diagnosis of AD or CU.
Sample size
Sample size was set at 325 patients aged over 18 with a
diagnosis of active or inactive psoriasis and 66 patients
in the control group (33 with AD and 33 with CU). The
sample size was calculated so as to allow for testing a
full range of psychometric characteristics and was based
specifically on the need to test sensitivity to change
which was considered to require the largest sample size.
Specifically, sample size for patients groups A and B was
calculated to be able to detect a change of 0.2 standard
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follow-up, with a p value of 0.01 and a statistical power
of 0.80 assuming a 10% loss to follow-up. Applying the
same criteria, and in order to detect a between-group
difference of 0.45 SDs with a ratio of inactive patients to
controls and active patients to controls of 1:2 and 1:3,
respectively, a sample size of 65 controls, 130 patients
with inactive psoriasis, and 195 patients with active
psoriasis was required.
Study instrumentation and variables
The primary study variable was the PSO-LIFE question-
naire. This was a self-administered questionnaire for
patients with psoriasis consisting of 20 items measuring
a range of HRQOL aspects relevant to individuals with
psoriasis (Additional file 1). The items refer to the previ-
ous 7 days and each item allows for a 5 point Likert
scale (response choices from Always to Never), Each re-
sponse is given a scoring from 1 (worst HRQOL) to 5
(best HRQOL). The overall questionnaire score is
obtained by adding up the 20-item responses and it
ranges from 20 to 100 points. In order to simplify its in-
terpretation and to validate the PSO-LIFE questionnaire,
the scoring was transformed to a 0 to 100 scale with a
higher score indicating better HRQOL.
The PSO-LIFE questionnaire was developed in a previ-
ous study phase using questionnaire development tech-
niques; according to FDA guidelines for patient-reported
outcome measure [20], a conceptual framework was
established for the questionnaire development. Psoriasis
is a dermatological disease which affects physical, emo-
tional and social well-being, these conform the HRQOL
in patients with psoriasis. The physical dimension is
affected through its symptoms; the psychological dimen-
sion is affected through anxiety, depression, lack of con-
centration and altering self-image; and it also affects the
social domain through the limitation on social/leisure
activities, disturbing sex life and causing work leave. The
questionnaire to be developed pretended to consider the
relationship among all these domains and their impact
on patient’s life. Considering all these aspects, the initial
point was the development of a specific questionnaire
that would provide physicians with a tool to assess
knowledge on the impact of psoriasis on the patient’s
quality of life.
Firstly, a literature review was performed to set the rela-
tion between psoriasis and patient’s self-perceived quality
of life; then, a qualitative assessment through a focus
group with 5 dermatologists was carried out to identify
the main domains affecting HRQOL in psoriasis patients,
As a second step, a semi-structured interview was con-
ducted with 20 psoriasis patients (10 with active and 10
with non active), from which several items were identified
to be related with psoriasis HRQOL; at the end of thisstage 139 preliminary statements were identified. Each of
the remaining items was subsequently rated by the derma-
tologist in terms of frequency, importance and clarity and
the number of items was reduced to a total of 37 items.
The selected items were edited in questionnaire format
and administered to a sample of 171 psoriasis patients
(52.1% active and 47.9% non active) to allow for a prelim-
inary factor analysis and Rasch analysis in order to obtain
the final version of the questionnaire. Factor analysis iden-
tified 6 preliminary dimensions (variance explained of
72.4%). The Rasch analysis was used to exclude those
items with INFIT or OUTFIT > 1.30 and <0.70 and those
which were redundant with other items. This final ques-
tionnaire, with a total of 20 items has good preliminary in-
ternal consistency (Cronbach’s alpha = 0.94) [18].
In the present study, socio-demographic variables col-
lected were age, sex, educational level (no education,
primary, secondary or tertiary level studies), and employ-
ment situation. Clinical variables collected in patients with
psoriasis included date of diagnosis, duration of latest
episode of active psoriasis, PASI index, current treat-
ment, recurrence or continuation of active episode (in
follow-up visits), and co-morbid chronic diseases. In
patients with AD, clinical variables included severity
of AD using the EASI index, disease intensity (using
a 4 point scale from none to severe), and treatment.
In patients with CU, variables collected included type
of CU, current symptoms, presence of wheals or lesions on
inclusion, and treatment.
As well as the PSO-LIFE questionnaire, all patients
also completed the Dermatology Life Quality Index
(DLQI) and patients in groups A and B also completed
the Psoriasis Disability Index (PDI). Both of these have
been adapted and validated for use in Spain [15][16].
The DLQI is a generic questionnaire designed for use in
patients with any type of skin disease. It consists of 10
items with a time-frame referring to the last 7 days and
measures the impact of disease in terms of symptoms,
daily activities, leisure, work/study, personal relation-
ships, and treatment. The score ranges from 0 (minimal
impact on HRQOL) to 30 (maximum impact on
HRQOL). The PDI is a disease-specific questionnaire
consisting of 15 items covering four dimensions of
HRQOL: daily activities, work/studies, personal relation-
ships, and leisure, with an additional item on treatment.
The overall score ranges from 0 to 45 with a higher
score indicating greater impact on HRQOL.
Data were also collected on patient perception of their
overall health state using a single item with 7 response
options. In the follow-up visits, patients were also asked
whether their overall health state had improved, deterio-
rated or remained the same, again using a 7 option re-
sponse scale from much improved to much worse
(health status transition item).
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The data analysis was performed using SPSS 15.0 for
Windows. A significance level of 0.05 was used in all
between-group comparisons.
The sample’s socio-demographic and clinical char-
acteristics were analyzed using descriptive statistics.
Parametric (Student’s t test and ANOVA) and non-
parametric (Mann-Whitney U, Kruskal-Wallis, chi-squared)
tests were used to test for between-group differences
while Friedman and Wilcoxon tests for paired data
were used to test for differences over time in the
PSO-LIFE index.
The feasibility of the PSO-LIFE questionnaire was
tested by analyzing the proportion of patients with miss-
ing responses on each item, and the proportion of
patients with no missing responses.
Score distributions were evaluated by calculating the
observed range of scores and the proportion of patients
with the worst and best possible scores (floor and ceiling
effects) on each dimension, as an indicator of the extent
to which scales capture the range of the underlying di-
mension. The reliability of the new questionnaire was
tested by examining the internal consistency of data in
the overall sample of psoriasis patients using Cronbach’s α.
Test-retest reliability was examined in patients (group A
and B) who reported no change on the health status transi-
tion item in the follow-up visit at 7 days and was analyzed
using the Intraclass Correlation Coefficient (ICC). For both
Cronbach’s α and the ICC, values over 0.7 were considered
acceptable [21].
Construct validity was tested in several ways. In the
first place, a principal components factor analysis was
performed with Varimax rotation to determine the
underlying dimensional structure of the questionnaire.
Screen plot analysis (based on eigenvalues –which cor-
respond to the variances of the factors– was also used in
deciding the number of factors in the questionnaire [22].
The questionnaire’s known groups’ validity (or capacity
to discriminate between groups expected to have differ-
ent scores [23]) was assessed by comparing scores on
the PSO-LIFE questionnaire between patients with active
and inactive psoriasis, and between those two groups
and the control group. We also expected patients with
visible lesions to score worse on the PSO-LIFE than
those without visible lesions, and we expected those with
mild psoriasis (PASI score <10) to score higher on the
PSO-LIFE (better HRQOL) than those having more se-
vere psoriasis (PASI score of 10 – 50). Between-group
differences were analyzed using linear regression models
and controlling for age and level of education (patients
vs. controls) and age, level of education, and duration of
last crisis (active vs. inactive psoriasis).
Convergent validity was tested by examining the ex-
tent to which scores on the PSO-LIFE demonstratedlogical relationships with the DLQI and PDI in the base-
line visit. We expected moderate to high correlations
with the DLQI and PDI overall scores and with most of
the individual dimensions on those questionnaires as
they measure similar content to the PSO-LIFE. Correla-
tions were calculated using Pearson and Spearman cor-
relation coefficients as appropriate. Correlations under
0.3 were considered weak, correlations between 0.3 and
0.5 were considered moderate, and those over 0.5 were
considered strong [24].
Longitudinal validity and sensitivity to change were
examined by comparing changes observed in PSO-LIFE
scores with those observed on the PASI Index, psoriasis
status, changes in treatment, and presence of adverse
effects as well as with changes in scores on the DLQI
and PDI, between baseline and the final visit. Changes in
PSO-LIFE score were analyzed by sub-groups based on
patient perceptions of overall change on completing the
study using the health status transition item. Effect sizes
were used to estimate the magnitude of changes. Effect
size was defined as the difference between baseline and
final visit mean scores divided by standard deviation at
baseline [24]. An effect size of 0.2 is equivalent to a
small effect size, 0.5 equates to a medium effect size,
and values of 0.8 or over equate to large effect sizes [24].
For comparison, effect sizes for the DLQI and PDI ques-
tionnaires were also calculated.
The minimum important difference (MID) is the smallest
difference in scores on a questionnaire that patients per-
ceive as beneficial [25]. The MID was estimated for the
PSO-LIFE questionnaire using results from patients who
reported having 'slightly improved' health status at 3 months
from baseline.Results
The final sample included for analysis consisted of 304
patients and 56 controls. Of the patients, 182 (50.6%)
were patients with active psoriasis and 122 (33.9%) had
inactive psoriasis, which was in accordance with the ini-
tially expected sample size, considering a 10% follow up.
Of the controls, 26 (7.2%) were patients with CU and 30
(8.3%) were patients with AD. Sample socio-
demographic and clinical characteristics at baseline are
shown in Table 1. The mean (SD) age of psoriasis
patients was 45.3 (14.5) years compared to 38.8 (14)
years for controls (p< 0.01). In the psoriasis group,
56.3% of patients were men compared to 51.8% in con-
trols (p = 0.54), and the control group showed higher
levels of education (46% who had completed university
level education compared to 24% of patients; p< 0.01).
In terms of clinical characteristics, patients reported a
mean of 18 years with the symptoms. The mean (SD)
PASI Index score at baseline was 17 (7.4) in patients
Table 1 Sample characteristics at baseline: controls, patients with active and inactive psoriasis
Patients (active psoriasis) N = 182 Patients (inactive psoriasis) N = 122 Controls N= 56 P**
Socio-demographic variables
Age, mean (SD), years 43.6 (14.7) 47.8 (14.0) 38.8 (14.0) <0.01
Male, n (%) 101 (55.5) 70 (57.4) 29 (51.8) 0.54
Highest educational level, n (%) <0.01
No formal education 5 (2.8) 4 (3.3) 4 (7.1)
Primary 66 (36.9) 46 (38.0) 11 (19.6)
Secondary 62 (34.6) 45 (37.2) 15 (26.8)
Post-secondary 46 (25.7) 26 (21.5) 26 (46.4)
Employment status, n (%) <0.05
Unemployed 19 (10.4) 12 (9.8) 6 (10.7)
Working – self-employed 26 (14.3) 11 (9.0) 10 (17.9)
Working – employed 87 (47.8) 59 (48.4) 28 (50.0)
Work disability 1 (0.5) 4 (3.3) 1 (1.8)
Pensioner/retired 19 (10.4) 25 (20.5) 3 (5.4)
Looking after home 22 (12.1) 9 (7.4) 7 (12.5)
Student 9 (4.9) 5 (4.1) 7 (12.5)
Clinical variables
Years since diagnosis, mean (SD) 18.6 (12.4) 17.8 (11.9) NS
PASI, n (%) <0.01
Mild (<10) 31 (17.0%) 98 (80.3%)
Moderate/severe≥ 10 151 (83.0%) 24 (19.7%)
Treatment*
Any 177 (97.3%) 104 (85.2%) <0.01
Topical 90 (49.5%) 44 (36.1%) <0.05
PUVA/Phototherapy 25 (13.7%) 10 (8.2%) NS
Systemic 101(55.5%) 54 (44.3%) NS
Biological 57 (31.3%) 59 (48.4%) <0.01
Other 32 (17.6%) 9 (7.4%) 0.01
PASI: Psoriasis Area Severity Index.
*Multi-response. The same patient could be in more than one category. Calculation performed for N = 304 (all patients).
**Statistically significant differences between patients and controls in proportion of Pensioners/retired.
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active psoriasis (p< 0.01).
Feasibility
In terms of feasibility, the items with the highest rate of
missing responses were items 15 and 16 which dealt
with problems in work/study. In this case, the highest
rate of non-response was among pensioners and house-
wives (<20% who failed to answer). Nevertheless, the
entire questionnaire was completed by over 95% of
patients, and therefore showed good feasibility (Table 2).
Reliability
No study patients obtained the minimum PSO-LIFE
score (floor effect) and only 3.2% obtained the maximum
score (ceiling effect). Reliability assessed in terms ofinternal consistency was excellent, with a Cronbach’s
alpha value of 0.948. Test-retest reliability, which was
assessed in patients who remained stable between base-
line and follow-up after 7 days (n = 149), was also excel-
lent with an ICC of 0.98 (Table 2).
Validity
Factor analysis showed the questionnaire to be essen-
tially unidimensional, with a single dimension explaining
50.9% of the variance in overall score. Screen plot ana-
lysis (Figure 1) also indicated a clear threshold of one
factor when distinguishing between factors with high
and low eigenvalues.
When PSO-LIFE scores were compared between
patients with psoriasis and controls, statistically signifi-
cant differences were observed (p = 0.03, adjusted by age
Table 2 Distribution characteristics and reliability of the PSO-LIFE questionnaire in psoriasis patients (active and
inactive): n = 304
Mean SD Missing items* Observed range Floor (%) Ceiling (%) Cronbach’s alpha ICC
PSO-LIFE overall score 64.9 22.4 4.6% 10-100 0% 3.2% 0.95 0.98
*Proportion of patients with a missing response on at least one item.
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tween those with active and inactive psoriasis was also
notable, with mean (SD) scores of 57.4 (20.4) and 76.4
(20.6), respectively (p< 0.01, adjusted by age, education
and duration of last outburst). On the other hand, statis-
tically significant differences were not observed be-
tween patients with inactive disease and the control
group (p> 0.05). Scores on the PSO-LIFE also varied
according to disease localization. Patients with visible
lesions (for example, on the head or upper extremities)
had a mean (SD) score of 63 (22) compared to 74.8 (23.9)
in patients with non-visible lesions and 78.5 (21.6) in
patients without lesions in the baseline visit (p< 0.01). Fi-
nally, statistically significant differences were also observed
between patients with mild disease and those with moder-
ate disease defined using the PASI (p< 0.01) (see Table 3).
In comparison with the other disease-specific instru-
ments used, the standardized differences in PSO-LIFE
scores between patients with active and inactive disease
were larger than the differences found on the DLQI and
PDI (standardized differences of 0.85 standard deviations
on the PSO-LIFE compared to 0.79 on the DLQI and
0.62 on the PDI).
The correlation between PSO-LIFE and PASI scores was
moderate (r =−0.43) while correlations with the DLQI and
PDI ranged from moderate to high (between −0.4 and −0.8
in the different questionnaires). The correlation with the
DLQI global score was r =−0.76 (p< 0.01) and with the
PDI overall score r =−0.76 (p< 0.01). The highest (nega-
















Figure 1 Screen plot analysis of factors in the PSO-LIFE questionnairethe DLQI were observed on the symptoms and percep-
tions dimension (r=−0.78, p< 0.01), followed by activities
of daily living and leisure (r =−0.66, p< 0.01). The lowest
correlation was seen with the DLQI work and study di-
mension (r =−0.40, p< 0.01). With the PDI, high correla-
tions were observed with daily activities and leisure
dimensions (r =−0.72 and −0.66, respectively; p< 0.01).
Overall, correlations were slightly higher with the DLQI
than with the PDI.
Longitudinal validity and sensitivity to change
The correlation coefficient between changes observed on the
PSO-LIFE and changes observed on the PASI index between
baseline and the final visit was r=−0.4 (p< 0.01). Patients
with active disease at baseline but who were inactive at study
completion showed a mean (SD) improvement in PSO-LIFE
score of 19.9 (15.1), while patients who still had active
disease at the end of the study improved by 10.1 (15.8)
points. Patients who had inactive disease throughout the
study improved by 7.7 (15.7) points, whilst those who be-
came active during the study showed a worsening in score of
8.2 (14.9) points (p< 0.01). On the other hand, no
differences in score changes were observed according to
whether the patients required a change in treatment or not
(p=0.94) or if they presented an adverse event during the
study (p=0.47), as these could occur at any time during
follow-up and the questionnaire measures HRQOL during
the last 7 days. Changes in score on the PSO-LIFE showed
moderate to high correlations with changes in score on the




Table 3 Known groups’ validity: PSO-LIFE scores
according to patient type, psoriasis status, localization,
and disease severity
Groups Mean PSO-LIFE score (SD) P value
Patient type 0.03
Psoriasis, n = 304 64.9 (22.5)
Control, n = 56 69.4 (17.3)
Psoriasis status <0.01
Active, n = 182 57.4 (20.4)
Inactive, n = 122 76.4 (20.6)
Localization <0.01
No lesions, n = 25 78.5 (21.6)
Trunk, lower extremities, n = 14 74.8 (23.9)
Head, upper extremities, n = 251 63.0 (21.9)
Psoriasis severity <0.01
Mild (PASI <10), n = 124 74.5 (22.0)
Moderate/severe≥ 10, n = 166 57.8 (20.1)
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patients who reported a ‘much improved’ health state on
completing the study was 1.01 (large effect size)
(Table 4). The effect size decreased as the reported over-
all change in health status diminished and, in patients
reporting an identical or very similar health state at the
end of the study, the effect size was 0.15 (small or null
effect size). The effect size for the sample that completed
the study was 0.5 (medium effect size), 0.73 for patients
with active psoriasis, and 0.29 for patients with inactive
psoriasis. Effect sizes for the DLQI and PDI were smaller
than for PSO-LIFE at 0.44 and 0.39, respectively.
The largest changes in PSO-LIFE scores over time
were seen for the group with active psoriasis at baseline.
Change over time was notably smaller in the inactive
disease group (see Figure 2).
The MID at 3 months was approximately 6.5 points.Table 4 PSO-LIFE scores at baseline and final visit, difference
change in psoriasis patients’ self-perceived health status




Much improved 62.3 22.0 84.5
Considerably improved 58.0 21.0 75.0
Slightly improved 68.5 22.6 75.0
More or less the same 73.5 20.6 76.5
Slightly worse 68.4 24.6 62.3
Considerably/Much worse 63.0 17.5 55.2
TOTAL 65.1 22.1 76.2Recommendations for PSO-LIFE questionnaire utilization
The PSO-LIFE questionnaire can also be used in clinical
practice obtaining the direct scores and without having
to transform them to a 0 to 100 scale. Using the score
obtained from a direct sum of items (ranging from 20 to
100) the MID at 3 months was approximately 5.2 points.
The transformation of scores does not affect the ques-
tionnaire validity, therefore, even though the validity
process was done using the transformed values, the
direct scores can also be used.
In terms of imputation to missing values, no assump-
tion of minimum requested items answered has been
made due to the low number of missing responses in the
validation study. Nevertheless, the authors recommend
that the number of missing items shouldn't be higher
than 25%, which corresponds to a maximum of 5 miss-
ing items in the PSO-LIFE questionnaire. In case of
missing items, they are given the value which is the
mean of the rest of the items which have been answered
by the patient.
Discussion
Numerous studies have shown that psoriasis has a nega-
tive impact on the quality of life of patients and family
members [3]. However, existing instruments have been
shown to have some drawbacks and none of them were
developed in Spain. This study has shown that the PSO-
LIFE questionnaire, a new tool for measuring HRQOL
in patients with psoriasis has good acceptability and ease
of administration together with excellent indices of reli-
ability, validity, and sensitivity to change. The PSO-LIFE
adds a further option in the range of instruments avail-
able to measure HRQOL in patients with psoriasis.
The fact that over 95% of patients completed all of the
items of the questionnaire suggests that the question-
naire is feasible, and may also suggest that the items are
generally relevant to patients. Interestingly, the items
with the highest rate of missing responses were the
items on the impact of the disease on work and study,in score between visits, and effect size according to
al (3 months) Difference n Effect
sizeSD Mean SD
13.4 22.2 20.4 69 1.01
17.6 17.1 12.8 67 0.81
20.1 6.5 10.3 39 0.29
20.6 3.0 9.8 62 0.15
22.4 −6.2 15.5 16 −0.25
17.4 −7.7 15.1 11 −0.44






























Baseline Visit 2 Final visit
ES = 0.73 
ES = 0.29
ES = 0.50 
Figure 2 Change in PSO-LIFE scores over the 3 month study period according to baseline group (active or non-active disease).
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observed among pensioners and students. A higher rate
of missing responses among the first group on these
items might be expected as they could consider the
items not relevant to them, though it is not so clear why
students should consider the items non-relevant. On the
other hand, even in these groups the rate of missing
responses was not too high, and we consider it essential
to maintain these items, given their relevance among
psoriasis sufferers in general [26].
Reliability coefficients, both in terms of internal
consistency and test-retest reliability were extremely
high, and easily exceeded the threshold of 0.70 suggested
as an indicator of satisfactory levels of reliability in this
type of instrument [21]. The results in terms of Cronbach’s
alpha compare favorably to coefficients observed for
psoriasis-specific outcomes such as the Psoriasis
Symptom Assessment (PSA) [27] or the PSORIQOL
as well as to dermatology-related instruments such as
the DLQI [27].
In terms of validity, we performed a wide range of
tests which generally indicated acceptable validity. Factor
analysis showed that the questionnaire was essentially
unidimensional. The undimensionality reflects the diver-
sity of the questions conforming this questionnaire, this
heterogeneity might be explained because of the short
number of items considered in the questionnaire (only
20) and the high number of factors that might affect
somehow the HRQOL in psoriasis patients; actually the
20 items assess symptomatology, emotional well-being,
personal and social relationships, as well as leisure.
Nevertheless the unidimensionality has some disad-
vantages, as it means that scores are not available for in-
dividual HRQOL dimensions, which might be of interest
from a clinical point of view. On the other hand, the
unidimensionality likely contributes to achieving the
high reliability coefficients observed here, which meansthat users can have substantial confidence in the scores
obtained. Likewise, the fact that the instrument is unidi-
mensional will facilitate scoring and the interpretation of
scores. When using multidimensional instruments,
patients may improve on some dimensions and worsen
on others, making it difficult to assess the overall direc-
tion of change.
Apart from the wide range of tests employed to exam-
ine the validity of the new instrument, other strengths of
the present study included the involvement of patients
with active and inactive disease, the use of control
groups, and testing of the sensitivity to change. The first
and last of these are related and were of considerable
relevance in this study as we were particularly interested
in developing and testing an instrument that would dis-
criminate well across the spectrum of disease, and which
would show good responsiveness, an aspect which has
not been determined for some available instruments [28]
or which has occasionally been shown to be unsatisfac-
tory [1]. Here, the PSO-LIFE questionnaire showed good
responsiveness and was noticeably more sensitive to
change than the DLQI or the PDI.
It is well known that some of the questions contained in
the existing questionnaires do not really fit within the
Spanish cultural way of living, as they have been devel-
oped with anglo-saxon patients. The fact that PSO-LIFE
has been developed in Spain makes it a very valid alterna-
tive, or even more appropriate, than the current existing
questionnaires in Spain, as well as in other Mediterranean
countries where the culture of the patients is similar to
Spain.
On the other hand, one of the limitations of the study
was that sensitivity to change was not tested in a before
and after design, i.e. by administering the test before and
after an intervention of known efficacy. Instead, we used
the approach of determining whether the instrument
was responsive to changes in patient’s self-assessed
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[29] but is widely used and provides at least provisional
evidence for the instrument’s sensitivity. Nevertheless,
future studies should test the instrument in a before and
after design. Another limitation of the study was that it
was only performed in patients with plaque psoriasis. Al-
though this was the main population of interest here
and it is the most frequent type of psoriasis, it would
nevertheless be useful to test the instrument in patients
with other types of psoriasis. Although representative-
ness is not an essential characteristic for this type of val-
idation study, which requires instead variety particularly
in clinical characteristics, a considerable number of cen-
ters participated from different regions in Spain in order
to collect the variability in terms of clinical practice.
Conclusions
We believe that the present results provide substantial
support for the reliability, validity, and responsiveness of
the PSO-LIFE questionnaire in the population for which
it was designed. There is also preliminary evidence for
superior discriminatory capacity and sensitivity to
change than other questionnaires frequently used in
these patients, i.e. the DLQI and the PDI. Further stud-
ies are required to assess the instrument’s responsiveness
in a before and after setting with an intervention of
known clinical efficacy and to test the instrument in
patients with other types of psoriasis. Adaptation and
validation of the instrument in other languages and set-
tings would also be useful in determining its potential
for use in multinational studies and for comparing the
HRQOL of psoriasis patients in different countries.
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